ArticleParkinsonism & related disorders2021
Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study.
Article in Parkinsonism & related disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Potential protein blood-based biomarkers for cognitive dysfunction in Parkinson's disease: a systematic review and network meta-analysis.Frontiers in aging neuroscience · 2026Pooled it
- Plasma neurofilament light chain in early Parkinson's disease predicts motor complications: a prospective cohort study.NPJ Parkinson's disease · 2026Article
- Region-specific transcriptional signatures of brain aging in the absence of neuropathology at the single-cell level.npj aging · 2026Article
- Serum p-tau217 Is a Prognostic Indicator of Cognitive Impairment in Idiopathic REM Sleep Behavior Disorder.Annals of neurology · 2026Article
- Regional cortical network atrophy predicts progression to dementia in the Lewy body diseases.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Region-Specific Transcriptional Signatures of Brain Aging in the Absence of Neuropathology at the Single-cell Level.bioRxiv : the preprint server for biology · 2025Article
- Positron Emission Tomography Imaging in Clinical Trials for Parkinson's Disease: Applications of Metabolic Brain Network Approach.Movement disorders : official journal of the Movement Disorder Society · 2025Review
- Evaluation of Plasma Neurodegenerative Biomarkers for Diagnosing Minimal Hepatic Encephalopathy and Predicting Overt Hepatic Encephalopathy in Chinese Patients with Hepatic Cirrhosis.Journal of clinical and translational hepatology · 2025Article
- Moderate intensity aerobic exercise alleviates motor deficits in 6-OHDA lesioned rats and reduces serum levels of biomarkers of Parkinson's disease severity without recovery of striatal dopamine or tyrosine hydroxylase.Experimental neurology · 2024Article
- Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson's Disease.NPJ Parkinson's disease · 2024Article
- Neurofilaments as biomarkers in neurological disorders - towards clinical application.Nature reviews. Neurology · 2024Review
- Relationship between plasma NFL and disease progression in Parkinson's disease: a prospective cohort study.Journal of neurology · 2024Article
- Serum neurofilament indicates accelerated neurodegeneration and predicts mortality in late-stage Parkinson's disease.NPJ Parkinson's disease · 2024Article
- Identification of Parkinson's disease subtypes with distinct brain atrophy progression and its association with clinical progression.Psychoradiology · 2024Article
- Association of Misfolded α-Synuclein Derived from Neuronal Exosomes in Blood with Parkinson's Disease Diagnosis and Duration.Journal of Parkinson's disease · 2024Article
- How should we be using biomarkers in trials of disease modification in Parkinson's disease?Brain : a journal of neurology · 2023Article
- Neurofilament light chain and cardiac MIBG uptake as predictors for phenoconversion in isolated REM sleep behavior disorder.Journal of neurology · 2023Article
- Blood neurofilament light chain in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Neurofilament Light Protein Predicts Disease Progression in Idiopathic REM Sleep Behavior Disorder.Journal of Parkinson's disease · 2023Article
- The 2022 Lady Estelle Wolfson lectureship on neurofilaments.Journal of neurochemistry · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Neurofilament light chain (NFL) level in biofluids is a sensitive measure of axonal damage and a promising biomarker in neurodegenerative diseases. In Parkinson's disease (PD), NFL can distinguish PD from other parkinsonian disorders, and NFL concentration is associated with disease severity, risk of progression, and survival. To determine whether serum NFL at baseline in de novo PD predicts motor decline, differentially impacts specific motor features, predicts cognitive decline, and predicts loss of dopamine terminals, here we evaluated 376 de novo PD patients from the PPMI database and analyzed the effect of baseline serum NFL levels on progression over eight years of motor impairment measured with the UPDRS, cognitive function measured with the MoCA, and putamen dopamine transporter (DAT) binding ratio measured with DaTscan. In longitudinal mixed effects models that controlled for age, gender, disease duration, and levodopa equivalent drug dose, higher levels of serum NFL at baseline were associated with greater increases of UPDRS-III and total UPDRS scores, with greater worsening of postural instability and gait disorder (PIGD) scores but not tremor scores over time. In contrast, baseline serum NFL was not associated with significant progression of MoCA scores in this de novo PD cohort. Higher baseline serum NFL was associated with greater reduction of putamen DAT binding ratio over time. Together, these findings show that baseline serum NFL levels predict the rate of motor decline, the accumulation of PIGD clinical features, and the progression of dopamine transporter loss in the early stage of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.